Asociación entre títulos de anticuerpos anticardiolipinas y eventos trombóticos

Article information

Resumen

Introducción

la trombosis es la manifestación principal del síndrome antifosfolípido (SAF); los marcadores serológicos de esta entidad son los anticuerpos anticardiolipinas (aCL), la anti-ß2 glicoproteína 1 y el anticoagulante lúpico. Aún se discute si los títulos de aCL o la presencia de un “segundo hit” son factores de riesgo para trombosis.

Objetivo

evaluar la asociación entre fenómenos trombóticos vasculares con la presencia y los títulos de aCL; además del papel de otros factores protrombóticos.

Material y método

estudio descriptivo transversal. Se revisaron historias clínicas de pacientes con sospecha clínica de SAF y con al menos una medición de títulos de aCL, se evaluó la presencia o no de eventos trombóticos y de comorbilidades (segundo hit).

Resultados

historias clínicas de 49 pacientes, 33 con un total de 36 eventos trombóticos de los cuales 23 ocurrieron en lechos venosos y 13 en lechos arteriales. Aunque la mayoría de los pacientes con títulos de aCL > 20 GLP o MLP se encontraban en el grupo de trombosis, no se encontró asociación significativa entre la presencia de trombosis y los títulos de aCL; como tampoco entre trombosis y la existencia de otras comorbilidades.

Conclusiones

los hallazgos encontrados permiten sugerir la mayor frecuencia de eventos trombóticos en pacientes con títulos de aCL < 40 en dos mediciones y aportan información sobre las características clínicas de los pacientes con aCL y sospecha de SAF en nuestro medio; sin embargo, no son suficientes para categorizarlos como un factor de riesgo definitivo de trombosis.

Palabras clave:

síndrome antifosfolípido

anticardiolipinas

trombosis

Summary

Background

thrombosis is the main clinical manifestation of the antiphospholipid syndrome (APS); anticardiolipin antibodies (aCL), anti-ß2 glycoprotein-1 antibodies and lupus anticoagulant are the serological markers of the disease. Whether the titles of aCL or the presence of a “second hit” are risk factors for thrombosis is an unresolved issue.

Objective

to evaluate the association between vascular thrombotic events with the presence of aCL. The relationship between thrombosis and the titles of aCL, as well as other prothrombotic factors was also assessed.

Methodology

descriptive cross-sectional study. The clinical charts of patients with possible APS and at least one laboratory measurement of aCL were reviewed. The presence of thrombotic events and the existence of comorbid states (second hit) were also evaluated.

Results

the records of 49 patients were assessed, 33 with a total of 36 thrombotic events, 23 had occurred on veins, and 13 on arteries. Though the majority of the patients that had titles of aCL above of 20 GPL or MPL were located in the group of thrombosis, there was no significant association between the titles of aCL and the presence of thrombosis. Neither significant association was found between thrombosis and the presence of other comorbid states.

Conclusions

these findings allow suggesting the increased frequency of thrombotic events in patients with titers of aCL lower than 40 twice and also add information about the clinical characteristics of patients with aCL and suspected APS in our region; however, they are not enough to categorize them as a definitive risk factor of thrombosis.

Key words:

antiphospholipid syndrome

anticardiolipin

thrombosis

Full text is only aviable in PDF

Referencias

[1.]

S. Miyakis, M.D. Lockshin, T. Atsumi, D.W. Branch, R.L. Brey, R. Cervera, et al.

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).

J Thromb Haemost, 4 (2006), pp. 295-306

http://dx.doi.org/10.1111/j.1538-7836.2006.01753.x | Medline

[2.]

R. Cervera, J.C. Piette, J. Font, M.A. Khamashta, Y. Shoenfeld, M.T. Camps, et al.

Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients.

Arthritis Rheum, 46 (2002), pp. 1019-1027

Medline

[3.]

F. Wisloff, E.M. Jacobsen, S. Liestol.

Laboratory diagnosis of the antiphospholipid syndrome.

Thromb Res, 108 (2002), pp. 263-271

Medline

[4.]

Anticardiolipin antibodies are an independent risk factor for first ischemic stroke.

The Antiphospholipid Antibodies in Stroke Study (APASS) Group.

Neurology, 43 (1993), pp. 2069-2073

Medline

[5.]

S.R. Levine, L. Salowich-Palm, K.L. Sawaya, M. Perry, H.J. Spencer, H.J. Winkler, et al.

IgG anticardiolipin antibody titer > 40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study.

Stroke, 28 (1997), pp. 1660-1665

Medline

[6.]

S.R. Levine, R.L. Brey, B.C. Tilley, J.L. Thompson, R.L. Sacco, R.R. Sciacca, et al.

Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke.

Jama, 291 (2004), pp. 576-584

http://dx.doi.org/10.1001/jama.291.5.576 | Medline

[7.]

M. Turiel, P. Sarzi-Puttini, R. Peretti, E. Rossi, F. Atzeni, W. Parsons, et al.

Thrombotic risk factors in primary antiphospholipid syndrome: a 5-year prospective study.

Stroke, 36 (2005), pp. 1490-1494

http://dx.doi.org/10.1161/01.STR.0000170645.40562.09 | Medline

[8.]

J.S. Ginsberg, P.S. Wells, P. Brill-Edwards, D. Donovan, K. Moffatt, M. Johnston, et al.

Antiphospholipid antibodies and venous thromboembolism.

Blood, 86 (1995), pp. 3685-3691

Medline

[9.]

E. Oger, C. Lernyer, M. Dueymes, E. Le Moigne, L. Bressolette, M. Escoffre, et al.

Association between IgM anticardiolipin antibodies and deep venous thrombosis in patients without systemic lupus erythematosus.

Lupus, 6 (1997), pp. 455-461

Medline

[10.]

I.A. Naess, S.C. Christiansen, S.C. Cannegieter, F.R. Rosendaal, J. Hammerstroem.

A prospective study of anticardiolipin antibodies as a risk factor for venous thrombosis in a general population (the HUNT study).

J Thromb Haemost, 4 (2006), pp. 44-49

http://dx.doi.org/10.1111/j.1538-7836.2005.01691.x | Medline

[11.]

R.T. Urbanus, B. Siegerink, M. Roest, F.R. Rosendaal, P.G. de Groot, A. Algra.

Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study.

Lancet Neurol, 8 (2009), pp. 998-1005

http://dx.doi.org/10.1016/S1474-4422(09)70239-X | Medline

[12.]

M. Hudson, A.L. Herr, J. Rauch, C. Neville, E. Chang, R. Ibrahim, et al.

The presence of multiple prothrombotic risk factors is associated with a higher risk of thrombosis in individuals with anticardiolipin antibodies.

J Rheumatol, 30 (2003), pp. 2385-2391

Medline

[13.]

W.F. Baker Jr., R.L. Bick, J. Fareed.

Controversies and Unresolved Issues in Antiphospholipid Syndrome Pathogenesis and Management.

Hematol Oncol Clin North Am, 22 (2008), pp. 155-174

http://dx.doi.org/10.1016/j.hoc.2007.10.006 | Medline

[14.]

J.A. Giron-Gonzalez, E. Garcia del Rio, C. Rodriguez, J. Rodriguez-Martorell, A. Serrano.

Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals.

J Rheumatol, (2004), pp. 1560-1567

[15.]

F. Vargas, L.F. Pinto.

Síndrome Antifosfolípido: morbilidad y evolución de una cohorte de pacientes del Hospital Pablo Tobón Uribe de Medellín-Colombia.

Revista Colombiana de Reumatología, 13 (2006), pp. 109-119

[16.]

G. Finazzi, V. Brancaccio, M. Moia, N. Ciaverella, M.G. Mazzucconi, P.C. Schinco, et al.

Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry.

Am J Med, 100 (1996), pp. 530-536

Medline

[17.]

I. Marai, Y. Levi, G. Godard, Y. Shoenfeld.

Following 90 patients with antiphospholipid syndrome with antibody titers and correlations with clinical manifestations: symptoms of the disease, a new antibody and correlations with clinical manifestations in the Israeli population.

Harefuah, 140 (2001), pp. 495-500

Medline

[18.]

J. Musial, J. Swadzba, A. Motyl, T. Iwaniec.

Clinical significance of antiphospholipid protein antibodies. Receiver operating characteristics plot analysis.

J Rheumatol, 30 (2003), pp. 723-730

Medline

[19.]

S. Sairam, B.A. Baethge, T. McNearney.

Analysis of risk factors and comorbid diseases in the development of thrombosis in patients with anticardiolipin antibodies.

Clin Rheumatol, 22 (2003), pp. 24-29

http://dx.doi.org/10.1007/s10067-002-0660-7 | Medline

[20.]

A. Ruffatti, T. Del Ross, M. Ciprian, M. Nuzzo, M. Rampudda, M.T. Bertero, et al.

Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study.

Ann Rheum Dis, 68 (2009), pp. 397-399

http://dx.doi.org/10.1136/ard.2008.096669 | Medline

[21.]

N.M. Amin.

Antiphospholipid syndromes in infectious diseases.

Hematol Oncol Clin North Am, 22 (2008), pp. 131-143

http://dx.doi.org/10.1016/j.hoc.2007.10.001 | Medline

[22.]

D. Sene, J.C. Piette, P. Cacoub.

Antiphospholipid antibodies, antiphospholipid syndrome and infections.

Autoimmun Rev, 7 (2008), pp. 272-277

http://dx.doi.org/10.1016/j.autrev.2007.10.001 | Medline

[23.]

A. Afeltra, M. Vadacca, L. Conti, S. Galluzzo, A.P. Mitterhofer, G.M. Ferri, et al.

Thrombosis in systemic lupus erythematosus: congenital and acquired risk factors.

Arthritis Rheum, 53 (2005), pp. 452-459

http://dx.doi.org/10.1002/art.21172 | Medline

[24.]

J.D. Torres, H. Cardona, L. Alvarez, W. Cardona-Maya, S.A. Castaneda, F. Quintero-Rivera, et al.

Inherited thrombophilia is associated with deep vein thrombosis in a Colombian population.

Am J Hematol, 81 (2006), pp. 933-937

http://dx.doi.org/10.1002/ajh.20733 | Medline

[25.]

W. Miesbach.

Neurologic symptoms as a feature of the antiphospholipid syndrome.

Semin Thromb Hemost, 34 (2008), pp. 286-289

http://dx.doi.org/10.1055/s-0028-1082273 | Medline

[26.]

J.F. Tellez-Zenteno, J.M. Remes-Troche, R.O. Negrete-Pulido, L. Davila-Maldonado.

Longitudinal myelitis associated with systemic lupus erythematosus: clinical features and magnetic resonance imaging of six cases.

Lupus, 10 (2001), pp. 851-856

Medline

[27.]

X. Lu, Y. Gu, Y. Wang, S. Chen, S. Ye.

Prognostic factors of lupus myelopathy.

Lupus, 17 (2008), pp. 323-328

http://dx.doi.org/10.1177/0961203307088005 | Medline

[28.]

D.P. D’Cruz, S. Mellor-Pita, B. Joven, G. Sanna, J. Allanson, J. Taylor, et al.

Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupus-like disease: good functional outcome and relevance of antiphospholipid antibodies.

J Rheumatol, 31 (2004), pp. 280-285

Medline

Indexed in:

Follow us:

Indexed in:

Follow us:

Subscribe to our newsletter